Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination?

Journal of Clinical Psychiatry

Volumn 60, Issue 9, 1999, Pages 613-616

  Levitt, Anthony J ^a,c   Joffe, Russell T ^b   Kamil, Rif ^c   McIntyre, Roger ^c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TREATMENT OUTCOME;

EID: 0032859192     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0908     Document Type: Article

References (15)

1. Nelson JC, Mazure CM, Bowers MB, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307
2. Eisen A. Fluoxetine and desipramine: a strategy for augmenting antidepressant response. Pharmacopsychiatry 1989;22:272-273
3. Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989;50:447-449
4. Weilburg JB, Rosenbaum JF, Meltzer-Brody S, et al. Tricyclic augmentation of fluoxetine. Ann Clin Psychiatry 1997;3:209-213
5. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-248
6. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-98
7. Endicott J, Spitzer RL. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1978;35:837-844
8. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
9. Aranow RB, Hudson JI, Pope HG, et al. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 1989;146:911-913
10. Michals M, Stanley DA, Crismon ML, et al. Elevated tricyclic antidepressant plasma concentrations associated with fluoxetine: two case reports [letter]. J Neuropsychiatry Clin Neurosci 1990;2:466-467
11. Vandel S, Bertschy G, Bonin B, et al. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology 1992;25:202-207
12. von Ammon C. Drug-drug interactions of fluoxetine with tricyclics. Psychosomatics 1990;31:273-276
13. Tyrer SP, Marshall EF, Griffiths HW. The relationship between response to fluoxetine, plasma drug levels, imipramine binding to platelet membranes and whole-blood 5-HT. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:797-805
14. Kelly MW, Perry PJ, Holstad SG, et al. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit 1989; 11:165-170
15. Koran LM, Cain JW, Dominguez RA, et al. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? Am J Psychiatry 1996;153:1450-1454